Ovarian cancer is the fifth largest cancer killer in women. Improved understanding of the
molecular pathways implicated in the pathogenesis of ovarian cancer has led to the …

Angiogenesis is a complex and highly regulated process that is crucial for tumor growth and
metastasis. Insights into the molecular mechanisms of tumor angiogenesis have led to the …

When to start and end antiangiogenesis therapy and the choice of optimal treatment
combinations remain controversial. Further evaluation of personalized novel angiogenesis …

Ovarian cancer is clinically characterized by advanced stage at presentation, transient
chemosensitivity, and stagnant long-term survivorship rates despite a broadening portfolio of …

Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality,
despite advances in surgical and chemotherapeutic management. The molecular pathways …

Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …

Results of standard chemotherapy in ovarian cancer are hampered by the development of
drug resistance leading to disease recurrence. This prompted interest in the development of …

Despite an aggressive approach of surgical cytoreduction and adjuvant combination
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …

Despite efforts to improve chemotherapeutic efficacy in epithelial ovarian cancer, outcome
for patients with advanced disease has remained unchanged since the introduction of …

Specific blocking of interactions between ligands and receptors along the angiogenic
pathways represents an effective approach for enhancing the efficacy as well as reducing …